Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2016 (2016), Article ID 4097398, 8 pages
http://dx.doi.org/10.1155/2016/4097398
Research Article

Prevention and Therapeutic Effects and Mechanisms of Tanshinone IIA Sodium Sulfonate on Acute Liver Injury Mice Model

1Department of Oncology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China
2Department of Radiation Genetics, School of Radiation Medicine and Protection, Soochow University School of Medicine, Suzhou 215123, China
3Department of Emergency, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou 215000, China
4Department of Radiation Oncology, The Affiliated Hospital of Jiangnan University, Wuxi 214062, China

Received 29 December 2015; Revised 31 March 2016; Accepted 7 April 2016

Academic Editor: Shun-Wan Chan

Copyright © 2016 Lunjie Lu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Jaeschke, Y. Xie, and M. R. McGill, “Acetaminophen-induced liver injury: from animal models to humans,” Journal of Clinical and Translational Hepatology, vol. 2, no. 3, pp. 153–161, 2014. View at Publisher · View at Google Scholar
  2. B. Rani, Y. Cao, A. Malfettone, C. Tomuleasa, I. Fabregat, and G. Giannelli, “Role of the tissue microenvironment as a therapeutic target in hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 20, no. 15, pp. 4128–4140, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Singanayagam and W. Bernal, “Update on acute liver failure,” Current Opinion in Critical Care, vol. 21, no. 2, pp. 134–141, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. V. Lo Re III, K. Haynes, K. A. Forde et al., “Risk of acute liver failure in patients with drug-induced liver injury: evaluation of Hy's law and a new prognostic model,” Clinical Gastroenterology and Hepatology, vol. 13, no. 13, pp. 2360–2368, 2015. View at Publisher · View at Google Scholar
  5. T. Khoury, A. A. Rmeileh, L. Yosha, A. A. Benson, S. Daher, and M. Mizrahix, “Drug induced liver injury: review with a focus on genetic factors, tissue diagnosis, and treatment options,” Journal of Clinical and Translational Hepatology, vol. 2, no. 2, pp. 99–108, 2015. View at Publisher · View at Google Scholar
  6. S. D. Shukla, A. Aroor, R. Restrepo, K. Kharbanda, and J. Ibdah, “In vivo acute on chronic ethanol effects in liver: a mouse model exhibiting exacerbated injury, altered metabolic and epigenetic responses,” Biomolecules, vol. 5, no. 4, pp. 3280–3294, 2015. View at Publisher · View at Google Scholar
  7. J. A. Richards, “Acute liver injury is independent of B cells or immunoglobulin M,” PLoS ONE, vol. 10, no. 9, Article ID e0138688, 2015. View at Google Scholar
  8. S. Xu and P. Liu, “Tanshinone II-A: new perspectives for old remedies,” Expert Opinion on Therapeutic Patents, vol. 23, no. 2, pp. 149–153, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Gao, Z. Liu, H. Li, P. J. Little, P. Liu, and S. Xu, “Cardiovascular actions and therapeutic potential of tanshinone IIA,” Atherosclerosis, vol. 220, no. 1, pp. 3–10, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Zhou, Z. Zuo, and M. S. S. Chow, “Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use,” Journal of Clinical Pharmacology, vol. 45, no. 12, pp. 1345–1359, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. Q. Shang, H. Xu, and L. Huang, “Tanshinone IIA: a promising natural cardioprotective agent,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 716459, 7 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. Q. Gu, H. Guan, Q. Shi, Y. Zhang, and H. Yang, “Curcumin attenuated acute Propionibacterium acnes-induced liver injury through inhibition of HMGB1 expression in mice,” International Immunopharmacology, vol. 24, no. 2, pp. 159–165, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. X. Jiang, Y. Chen, H. Zhu et al., “Sodium tanshinone IIA sulfonate ameliorates bladder fibrosis in a rat model of partial bladder outlet obstruction by inhibiting the TGF-β/Smad pathway activation,” PLoS ONE, vol. 10, no. 6, Article ID e0129655, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Jiao, C. Liu, F.-M. Cui et al., “Long intergenic non-coding RNA induced by X-ray irradiation regulates DNA damage response signaling in the human bronchial epithelial BEAS-2B cell line,” Oncology Letters, vol. 9, no. 1, pp. 169–176, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Saracyn, R. Zdanowski, M. Brytan et al., “D-galactosamine intoxication in experimental animals: is it only an experimental model of acute liver failure,” Medical Science Monitor, vol. 21, pp. 1469–1477, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. Q. Ruan, F. Liu, Z. Gao et al., “The anti-inflamm-aging and hepatoprotective effects of huperzine A in d-galactose-treated rats,” Mechanisms of Ageing and Development, vol. 134, no. 3-4, pp. 89–97, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Luo, Y. Zhang, X. Hu et al., “The effects of modified sini decoction on liver injury and regeneration in acute liver failure induced by d-galactosamine in rats,” Journal of Ethnopharmacology, vol. 161, pp. 53–59, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Tillhon, L. M. Guamán Ortiz, P. Lombardi, and A. I. Scovassi, “Berberine: new perspectives for old remedies,” Biochemical Pharmacology, vol. 84, no. 10, pp. 1260–1267, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Zhang, W.-Y. Sun, J.-J. Wu, and W. Wei, “TGF-β signaling pathway as a pharmacological target in liver diseases,” Pharmacological Research, vol. 85, pp. 15–22, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Karimi-Googheri, H. Daneshvar, R. Nosratabadi et al., “Important roles played by TGF-β in hepatitis B infection,” Journal of Medical Virology, vol. 86, no. 1, pp. 102–108, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Yoshida, M. Murata, T. Yamaguchi, and K. Matsuzaki, “TGF-β/smad signaling during hepatic fibro-carcinogenesis (review),” International Journal of Oncology, vol. 45, no. 4, pp. 1363–1371, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. C.-M. Lee, J. W. Park, W.-K. Cho et al., “Modifiers of TGF-β1 effector function as novel therapeutic targets of pulmonary fibrosis,” Korean Journal of Internal Medicine, vol. 29, no. 3, pp. 281–290, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Nikolaou, M. Sarris, and I. Talianidis, “Molecular pathways: the complex roles of inflammation pathways in the development and treatment of liver cancer,” Clinical Cancer Research, vol. 19, no. 11, pp. 2810–2816, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Wang, “Molecular mechanisms of hepatic apoptosis regulated by nuclear factors,” Cellular Signalling, vol. 27, no. 4, pp. 729–738, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Fan, R. Mao, and J. Yang, “NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer,” Protein and Cell, vol. 4, no. 3, pp. 176–185, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. W. Li, J. Li, M. Ashok et al., “A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1,” The Journal of Immunology, vol. 178, no. 6, pp. 3856–3864, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Wang, X. Zhang, L. Liu et al., “Tanshinone II A down-regulates HMGB1, RAGE, TLR4, NF-κB expression, ameliorates BBB permeability and endothelial cell function, and protects rat brains against focal ischemia,” Brain Research, vol. 1321, pp. 143–151, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Bridges and A. R. Saltiel, “Phosphoinositides: key modulators of energy metabolism,” Biochimica et Biophysica Acta, vol. 1851, no. 6, pp. 857–866, 2015. View at Publisher · View at Google Scholar
  29. B. D. Manning and L. C. Cantley, “AKT/PKB signaling: navigating downstream,” Cell, vol. 129, no. 7, pp. 1261–1274, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Romeo, X. Zhang, and P. P. Roux, “Regulation and function of the RSK family of protein kinases,” Biochemical Journal, vol. 441, no. 2, pp. 553–569, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. M. C. Mendoza, E. E. Er, and J. Blenis, “The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation,” Trends in Biochemical Sciences, vol. 36, no. 6, pp. 320–328, 2011. View at Publisher · View at Google Scholar · View at Scopus